Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: Closing the gap between benefit and toxicity?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 3, 2009, Pages 484-498

  Buchmann, Inga ^a   Meyer, Ralf G ^b   Mier, Walter ^a   Haberkorn, Uwe ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Leukaemia; Multiple myeloma; Myeloablative conditioning; Myeloablative radioimmunotherapy; Stem cell transplantation

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM 225; BISMUTH 213; CD33 ANTIGEN; CD45 ANTIGEN; CD66 ANTIGEN; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BW 250 183; MONOCLONAL ANTIBODY M 195; MONOCLONAL ANTIBODY TC 99M; MYELOABLATIVE AGENT; PENTETIC ACID; PENTETIC ACID YTTRIUM 90; RHENIUM 188; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ISOTOPE LABELING; MYELOABLATIVE CONDITIONING; NONHUMAN; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCONJUGATES; LEUKEMIA; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; NEURAL TUBE DEFECTS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; TRANSPLANTATION CONDITIONING;

EID: 60649091665     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0996-6     Document Type: Review

References (54)

1. N Kröger 2007 Mini-Midi-Maxi? How to harness the graft-versus myeloma effect and target molecular remission after allogeneic stem cell transplantation Leukemia 21 1851 1858
2. D Blaise N Vey C Faucher M Mohty 2007 Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukaemia Haematologica 92 533 541
3. DA Mulford DA Scheinberg JG Jurcic 2005 The promise of targeted [alpha]-particle therapy J Nucl Med 46 Suppl 1 1995 2045
4. JG Jurcic 2001 Antibody therapy for residual disease in acute myelogenous leukemia Crit Rev Oncol Hematol 38 37 45
5. A Chaidos E Kanfer JF Apperley 2007 Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage Best Pract Res Clin Haematol 20 125 154
6. AH Goldstone SM Richards HM Lazarus 2008 In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Blood 111 1827 1833
7. K Wheatley AK Burnett AH Goldstone 1999 A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties Br J Haematol 107 69 79
8. PD Kottaridis RE Gale ME Frew 2001 The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 1752 1759
9. C Preudhomme C Sagot N Boissel N 2002 Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) Blood 100 2717 2723
10. RA Clift CD Buckner FR Appelbaum 1990 Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimen Blood 76 1867 1871
11. JW Vardiman NL Harris RD Brunning 2002 The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2292 2302
12. N Kröger M Bornhäuser G Ehninger 2003 Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia Ann Hematol 82 336 342
13. R Martino S Iacobelli R Brand Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group 2006 Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood 108 836 846
14. M Attal JL Harousseau AM Stoppa 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome N Engl J Med 335 91 97
15. JA Child GJ Morgan FE Davies Medical Research Council Adult Leukaemia Working Party 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875 83
16. B Barlogie RA Kyle KC Anderson 2006 Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 J Clin Oncol 24 929 936
17. W Matsui CA Huff O Wang 2004 Characterization of clonogenic multiple myeloma cells Blood 103 2332 2336
18. GW Santos PJ Tutschka R Brookmeyer 1983 Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide regimen N Engl J Med 309 1347 1353
19. EA Copelan 2006 Hematopoietic stem cell transplantation New Engl J 354 1813 1826
20. JL Ferrara P Reddy 2006 Pathophysiology of graft-versus-host disease Semin Hematol 43 3 10
21. GR Hill JM Crawford KR Cooke 1997 Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines Blood 8 3204 3213
22. E Holler HJ Kolb J Mittermüller 1995 Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F) Blood 86 890 899
23. JE Levine JP Uberti L Ayash 2003 Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy Biol Blood Marrow Transplant 9 189 197
24. JM Boiron D Lerner A Pigneux 2001 Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients Leuk Lymphoma 41 285 296
25. A Newland 2002 Progress in the treatment of acute myeloid leukaemia in adults Int J Hematol 76 Suppl 1 253 258
26. RP Witherspoon HJ Deeg B Storer 2001 Haematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia J Clin Oncol 19 2134 2141
27. D Valcarcel R Martino D Caballero 2008 Sustained remissions of high-risk acute myeloid leukaemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival J Clin Oncol 26 577 584
28. DC Matthews FR Appelbaum JF Eary 1995 Development of a marrow transplantation regimen for acute leukemia using targeted haematopoietic irradiation delivered by I-131-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation Blood 85 1122 1131
29. I Buchmann D Bunjes J Kotzerke 2002 Myeloablative radioimmunotherapy with Re-188-anti-CD66-Antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation Cancer Biother Radiopharm 17 151 163
30. CM Richman SJ Denardo RT O'Donnell 2005 High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody Clin Cancer Res 11 5920 5927
31. TM Behr F Griesinger J Riggert 2002 High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study Cancer 94 4 suppl 1363 1372
32. A Nademanee S Forman A Molina 2005 A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma Blood 106 2896 2902
33. D Bunjes I Buchmann C Duncker 2001 Re-188-labeled anti-CD 66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukaemia or myelodysplastic syndrome: results of a phase I-II study Blood 98 565 572
34. Loevinger R, Berman MA. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. Society of Nuclear Medicine, New York; 1976, MIRD Pamphlet No. 1.
35. L Camera S Kinuya K Garmestani 1994 Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies J Nucl Med 35 882 889
36. T Zenz RF Schlenk G Glatting 2006 Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation J Nucl Med 47 278 286
37. A Frilling F Weber F Saner 2006 Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors Surgery 140 968 976
38. R Ratei L Karawajew R Schabath 2008 Differential expression of the carcinoembryonic antigen-related cell adhesion molecules panCD66, CD66a, CD66c and of sialyl-Lewis x (CD15s) on blast cells of acute leukemias Int J Hematol 87 137 143
39. DA Scheinberg M Tanimoto S McKenzie 1989 Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia Leukemia 3 440 445
40. PC Caron MS Co MK Bull 1992 Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies Cancer Res 52 6761 6767
41. PC Caron JG Jurcic AM Scott 1994 A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity Blood 83 1760 1768
42. DC Matthews FR Appelbaum JF Eary 1999 Phase I study of I-131-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome Blood 94 1237 1247
43. I Buchmann T Kull G Glatting 2003 A comparison of biodistribution and biokinetics of 99mTc-anti-CD66-mAb BW250/183 and 99mTc-anti-CD45-mAb YTH24.5 with regard to suitability for myeloablative radioimmunotherapy Eur J Nucl Med Mol Imaging 30 667 673
44. G Glatting M Müller B Koop 2006 Anti-CD45 monoclonal antibody YAML568: a promising radioimmunoconjugate for targeted radioimmunotherapy for acute leukemia J Nucl Med 47 1335 1341
45. MA Schwartz DR Lovett A Redner 1993 Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias J Clin Oncol 11 294 303
46. JG Jurcic T DeBlasio L Dumont 2000 Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia Clin Cancer Res 6 372 380
47. D Bunjes 2002 Re-188-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia Leuk Lymphoma 43 2125 2131
48. SN Reske D Bunjes I Buchmann 2001 Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation Eur J Nucl Med 28 807 815
49. M Ringhoffer N Blumstein B Neumaier 2005 188Re or 90Y-labeled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study Br J Haematol 130 604 613
50. Orchard KH, Cooper M, Lewington V, et al. Targeted radiotherapy in haematopoietic stem cell transplantation: results of a phase I trial using a yttrium-90-labelled anti-CD66 murine monoclonal antibody demonstrating consistent BM targeting. Bone Marrow Transplant 2006;37(Suppl), p. 45, O338.
51. JG Jurcic PC Caron TK Nikula 1995 Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Res 55 Suppl 5908s 5910s
52. JG Jurcic SM Larson G Sgouros 2002 Targeted alpha particle immunotherapy for myeloid leukemia Blood 100 1233 1239
53. I Buchmann J Mutschler G Steinbach 2002 Myeloablative radioimmunotherapy with Re-188-anti-CD66-mAb before stem cell transplantation does not increase cytokine levels [abstract] J Nucl Med 43 Suppl 314P
54. I Buchmann A Schultz M Sparber 2002 Myeloablative radioimmunotherapy with Re-188-anti-CD66-mAb in paediatric leukaemia patients: a phase I-trial J Nucl Med 43 Suppl 37P